CLINICAL TRIALS PROFILE FOR DENOSUMAB
✉ Email this page to a colleague
Biosimilar Clinical Trials for denosumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03293108 ↗ | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women | Active, not recruiting | AryoGen Pharmed Co. | Phase 3 | 2017-04-29 | The purpose of this study is to compare the efficacy and safety of Denosumab 60 mg produced by AryoGen Pharmed and Amgen Denosumab 60 mg among osteoporotic postmenopausal women. Postmenopausal women diagnosed with osteoporosis according to their Bone mineral density result (BMD), aged between 45 to 75 are included in this trial. This is a Phase III, randomized, two armed, double-blind, parallel, active-controlled,non-inferiority clinical trial. The eligible patients are randomized in a 1:1 ratio to receive Arylia or Prolia® subcutaneous injections, at the beginning of the trial and every 6 months at month 6 and 12, in an 18-month study period. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study. The primary objective of this study is to assess non-inferiority of test- Denosumab 60 mg (Arylia) to the reference Denosumab 60 mg (Prolia®) in terms of efficacy among osteoporotic postmenopausal women. The secondary objectives of this study are: To further compare efficacy of test- Denosumab 60 mg to reference Denosumab 60 mg; To assess the safety of test- Denosumab 60 mg compared to reference Denosumab 60 mg. |
| NCT04664959 ↗ | A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis | Active, not recruiting | Samsung Bioepis Co., Ltd. | Phase 3 | 2020-11-26 | This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis. |
| NCT04934072 ↗ | A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis | Recruiting | Fresenius Kabi SwissBioSim GmbH | Phase 3 | 2021-07-05 | The primary objective of this study is to demonstrate equivalent efficacy of FKS518 to US-licensed Prolia in women with postmenopausal osteoporosis (PMO). Participants will be randomized at the beginning of the Double-blind Core Treatment Period (Baseline to Week 52) to receive either FKS518 or US-licensed Prolia on Day 1, and then every 26 weeks for up to 52 weeks. At the beginning of the Double-blind Transition Period (Week 52 to Week 78), participants who received US-licensed Prolia will be re-randomized to either continue receiving US-licensed Prolia every 26 weeks for up to 78 weeks, or switch to receive FKS518 every 26 weeks for up to 78 weeks. Participants who were randomized to receive FKS518 at the beginning of the Double-blind Core Treatment Period will continue to receive this treatment during the Double-blind Transition Period. For Marketing Authorization Application (MAA) in the EU and European Economic Area (EEA) only: The primary objective is to demonstrate equivalent efficacy and pharmacodynamics of the proposed biosimilar denosumab FKS518 to US-Prolia in women with PMO. |
| NCT05299073 ↗ | A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva | Recruiting | mAbxience S.A | Phase 1 | 2022-03-01 | Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the PK, PD, safety and immunogenicity profile of MB09 with EU/US-Xgeva® in healthy male subjects. During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Pharmacodynamics, safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout. |
| NCT05338086 ↗ | A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study) | Recruiting | mAbxience S.A | Phase 3 | 2022-03-31 | This is a randomized, double-blind, parallel, multicenter, multinational study to compare the efficacy, pharmacokinetics, pharmacodynamics, safety and immunogenicity of MB09 versus Prolia® in postmenopausal women with osteoporosis |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for denosumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00043186 ↗ | Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density | Completed | Amgen | Phase 2 | 2002-05-01 | To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD. The clinical hypothesis is that denosumab subcutaneous injections administered every 3 or 6 months for 12 months will significantly increase lumbar spine bone mineral density and will be well tolerated. |
| NCT00089791 ↗ | A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis | Completed | Amgen | Phase 3 | 2004-08-01 | This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis. |
| NCT00091832 ↗ | Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer | Completed | Amgen | Phase 2 | 2004-09-01 | This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication. |
| NCT00095498 ↗ | Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis | Completed | Amgen | Phase 2 | 2004-08-11 | This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA). |
| NCT00259740 ↗ | Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab | Completed | Amgen | Phase 2 | 2005-11-01 | The purpose of this study is to determine if denosumab is effective in the treatment of relapsed or plateau-phase multiple myeloma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for denosumab
Condition Name
Clinical Trial Locations for denosumab
Trials by Country
Clinical Trial Progress for denosumab
Clinical Trial Phase
Clinical Trial Sponsors for denosumab
Sponsor Name
